We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





CerTest Demonstrates VIASURE Real Time PCR Complete Solution at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023

CerTest Biotec (Zaragoza, Spain) is presenting several novel products for research and diagnosis at Medlab Middle East 2023, including its VIASURE Real Time PCR Complete Solution, along with equipment and reagents for CLIA. More...

The VIASURE Complete Solution comprises the VIASURE RNA/DNA extraction kits, the V-FLEX nucleic acid extraction and PCR set-up system, V-Lab96 Real Time PCR system and V-Smart automatic interpretation software.

The VIASURE V-FLEX system is a fully automated solution in molecular biology for nucleic acid extraction, purification and PCR set-up from biological matrix and samples. The instrument has been designed with flexible configuration, in order to meet different user needs. The VIASURE V-Lab96 Advanced Real Time PCR System with 96-well block for high sample throughput in diagnostic lab applications. VIASURE V-Lab96 allows users to analyze 96 samples simultaneously for qualitative and quantitative PCR. The VIASURE V-Smart software for the analysis and interpretation of VIASURE RT PCR assays facilitates the conversion of the PCR raw data into test results with minimal manual intervention. Additionally, VIASURE Real Time PCR Detection Kits allow for simultaneous detection of multiple targets in a broad range of multiplexing diagnostic panels, including in the area of antimicrobial resistance.

Recently, CerTest had announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.

Related Links:
CerTest Biotec


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gastrointestinal Panel
Xpert® GI Panel
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.